Extension Study of the U-LaserPrint-1 Clinical Trial
Key facts
- Where
- Athens, GörögországSee the 2 sites
- Phase
- 1/2. fázis
Where in Görögország
- General Hospital of Athens "G. Gennimatas"Athens, GörögországToborzás még nem indult
- Laiko General Hospital of AthensAthens, GörögországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Phosprint S.A.
- Trial code
- EU 2026-527804-26-00
- Record updated
- 2026. szeptember 17.
- Original description
To collect additional data to evaluate the long-term safety of the InvivoLPrint-U therapy (a combination of bioprinted cultured autologous urothelial cells and their administration using the corresponding bioprinter) in the context of neobladder reconstruction surgery conducted as part of the U-LaserPrint-1 clinical trial.Read full original descriptionShow less
A follow-up extension study of patients who completed the U-LaserPrint-1 clinical trial to evaluate the long-term safety and efficacy of treatment with InvivoLPrint-U.
To collect additional data to evaluate the long-term safety of the InvivoLPrint-U therapy (a combination of bioprinted cultured autologous urothelial cells and their administration using the corresponding bioprinter) in the context of neobladder reconstruction surgery conducted as part of the U-LaserPrint-1 clinical trial.
Inclusion: Participation in and completion of the U-LaserPrint-1 clinical trial; Provision of written informed consent.
Exclusion: Refusal to participate in the extension study; Non-compliance with the protocol procedures during the conduct of the U-LaserPrint-1 clinical trial and/or inability to comply with the follow-up requirements of the extension study protocol.